+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pharmaceutical Market Size, Share & Trends Analysis Report by Molecule Type, Product, Type, Disease, Age Group, Route of Administration, Distribution Channel, and Region with Growth Forecasts, 2025-2030- Product Image
Pharmaceutical Market Size, Share & Trends Analysis Report by Molecule Type, Product, Type, Disease, Age Group, Route of Administration, Distribution Channel, and Region with Growth Forecasts, 2025-2030- Product Image
New

Pharmaceutical Market Size, Share & Trends Analysis Report by Molecule Type, Product, Type, Disease, Age Group, Route of Administration, Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 250 Pages
  • February 2025
  • Region: Global
  • Grand View Research
  • ID: 5921093
Description Jump to:
The Pharmaceutical Market was valued at USD 1.64 Trillion in 2024, and is projected to reach USD 2.35 Trillion by 2030, rising at a CAGR of 6.12%. The growth of the pharmaceuticals market is attributable to the increasing prevalence of chronic diseases, leading to a growing need for developing novel therapeutics. According to the National Council on Aging, it is estimated that approximately 95% of the older population has at least one chronic ailment, and around 80% has two or more. Moreover, chronic diseases such as diabetes, arthritis, and heart disease disproportionately affect the elderly population.

Awareness is critical for prevention, early detection, focused therapy, and effective treatment. People aware of an illness and its symptoms are more inclined to take preventative measures, such as screenings, tests, and check-ups. The increased awareness of various diseases is another element driving the pharmaceutical space. As people are now aware of diseases such as cancer and diabetes, they are more likely to seek treatment if they develop those conditions. A number of initiatives are taken by public and private organizations to spread awareness and educate the population. Furthermore, many people now have insurance policies that cover prescription drug expenses, contributing to increased pharmaceutical demand.

Moreover,the demand for pharmaceuticals is significantly increasing globally due to advancements in technology in the development of novel therapeutics. The pharmaceutical industry invests at an unprecedented rate in research and development, as well as product sales and distribution. The industry focuses on distinctly and directly addressing people's health. The pharmaceuticals industry is critical to patient care and community development and provides numerous life-saving treatments, generates employment, and contributes to the world economy.

Many biological agents, such as bacteria and viruses, are used in vaccine manufacturing, fermentation processes, and biotechnology. The market is made up of a diverse spectrum of companies, including giant pharma, mid-sized specialty, virtual pharma, generic manufacturers, and small biotechnology and biopharmaceutical organizations. Furthermore, key players involved in developing and formulating various therapeutic formulations are focusing on collaborations and partnerships to develop novel medications and maintain their competitive position in the market.

Moreover, several players are involved in developing novel pharmaceuticals to meet the rising demand for the prevention and treatment of conditions. For instance, in April 2023, F. Hoffmann-La Roche Ltd. announced that its wet age-related macular degeneration drug, Vabysmo, which received FDA approval in January 2022, brought around USD 500 million during the first quarter of 2023. The drug's sales increased by more than 500% year-on-year, beating competitors such as multiple sclerosis treatment Ocrevus and the hemophilia medication Hemlibra. Moreover, in July 2023, Novartis AG received U.S. FDA approval for an expanded indication of Leqvio (inclisiran), in order to include treatment of patients with high LDL-C who are at an increased risk of heart diseases.

Pharmaceutical Market Report Highlights

  • The Conventional drugs (small molecules) dominated the market with a revenue share of 54.74% in 2024.
  • The branded segment dominated the pharmaceutical market with a revenue share of 86.76% in 2024.
  • The prescription segment dominated the market with a revenue share of 86.76% in 2024 due to rising demand for chronic disease treatments, technological advancements in drug development, and improved healthcare access.
  • The cancer segment dominated the market with a revenue share of 18.06% in 2024.
  • The oral segment dominated the peptide drug conjugates market with a revenue share of 57.53% in 2024 due to its convenience, patient compliance, and cost-effectiveness.
  • The adults segment dominated the peptide drug conjugates market with a revenue share of 63.84% in 2024.
  • The hospital pharmacy segment dominated the peptide drug conjugates market with a revenue share of 53.53% in 2024

This report addresses:

  • Market intelligence to enable effective decision-making.
  • Market estimates and forecasts from 2018 to 2030.
  • Growth opportunities and trend analyses.
  • Segment and regional revenue forecasts for market assessment.
  • Competition strategy and market share analysis.
  • Product innovation listings for you to stay ahead of the curve.
  • COVID-19's impact and how to sustain in this fast-evolving market.

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Pharmaceutical Market Variables, Trends, & Scope
3.1. Parent Market Outlook
3.2. Ancillary Market Outlook
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.1.1. Advancement in therapeutics and robust product pipeline
3.3.1.2. Rise in pharmaceutical r&d spending
3.3.1.3. Rise in pharmaceutical r&d spending
3.3.2. Market Restraints Analysis
3.3.2.1. Patent expiration of key market drugs
3.3.2.2. Pricing pressures on bio/pharmaceutical companies
3.3.2.3. Stringent regulatory scenario
3.4. Dopamine Agonist Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
3.5. Pipeline Analysis
3.5.1. Phase 1
3.5.2. Phase 2
3.5.3. Phase 3
Chapter 4. Pharmaceutical Market: By Drug Estimates & Trend Analysis
4.1. Pharmaceutical Market: Drug Segment Dashboard
4.2. Pharmaceutical Market: By Drug Movement Analysis, USD Million, 2024 & 2030
4.3. Biologics & Biosimilars (Large Molecules)
4.3.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.3.2. Monoclonal Antibodies
4.3.2.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
4.3.3. Vaccines
4.3.3.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
4.3.4. Cell & Gene Therapy
4.3.4.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
4.3.5. Others
4.3.5.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
4.4. Conventional Drugs (Small Molecules)
4.4.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 5. Pharmaceutical Market: Type Estimates & Trend Analysis
5.1. Pharmaceutical Market: Type Segment Dashboard
5.2. Pharmaceutical Market: By Product Movement Analysis, USD Million, 2024 & 2030
5.3. Prescription
5.3.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
5.4. OTC
5.4.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 6. Pharmaceutical Market: Product Estimates & Trend Analysis
6.1. Pharmaceutical Market: Product Segment Dashboard
6.2. Pharmaceutical Market: By Product Movement Analysis, USD Million, 2024 & 2030
6.3. Branded
6.3.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4. Generics
6.4.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 7. Pharmaceutical Market: Disease Estimates & Trend Analysis
7.1. Pharmaceutical Market: Disease Segment Dashboard
7.2. Pharmaceutical Market: By Disease Movement Analysis, USD Million, 2024 & 2030
7.3. Cardiovascular diseases
7.3.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
7.4. Cancer
7.4.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5. Diabetes
7.5.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6. Infectious diseases
7.6.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
7.7. Neurological disorders
7.7.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
7.8. Respiratory diseases
7.8.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
7.9. Autoimmune diseases
7.9.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
7.10. Mental health disorders
7.10.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
7.11. Gastrointestinal disorders
7.11.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
7.12. Women’s Health Diseases
7.12.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
7.13. Genetic and Rare genetic diseases
7.13.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
7.14. Dermatological conditions
7.14.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
7.15. Obesity
7.15.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
7.16. Renal diseases
7.16.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
7.17. Liver conditions
7.17.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
7.18. Hematological disorders
7.18.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
7.19. Eye conditions
7.19.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
7.20. Infertility conditions
7.20.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
7.21. Endocrine disorders
7.21.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
7.22. Allergies
7.22.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
7.23. Others
7.23.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 8. Pharmaceutical Market: Route of Administration Estimates & Trend Analysis
8.1. Pharmaceutical Market: Route of Administration Segment Dashboard
8.2. Pharmaceutical Market: By Route of Administration Movement Analysis, USD Million, 2024 & 2030
8.3. Oral
8.3.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
8.3.2. Tablets
8.3.3. Capsules
8.3.4. Suspensions
8.3.5. Other
8.4. Topical
8.4.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5. Parenteral
8.5.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.2. Intravenous
8.5.3. Intramuscular
8.6. Inhalations
8.6.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
8.7. Other Routes of Administration
8.7.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 9. Pharmaceutical Market: Age Group Estimates & Trend Analysis
9.1. Pharmaceutical Market: Age Group Segment Dashboard
9.2. Pharmaceutical Market: By Age Group Movement Analysis, USD Million, 2024 & 2030
9.3. Children & Adolescents
9.3.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
9.4. Adults
9.4.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
9.5. Geriatric
9.5.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 10. Pharmaceutical Market: Distribution Channel Estimates & Trend Analysis
10.1. Pharmaceutical Market: Distribution Channel Segment Dashboard
10.2. Pharmaceutical Market: By Distribution Channel Movement Analysis, USD Million, 2024 & 2030
10.3. Hospital Pharmacy
10.3.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
10.4. Retail Pharmacy
10.4.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
10.5. Others
10.5.1. Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 11. Pharmaceutical Market: Regional Estimates & Trend Analysis
11.1. Pharmaceutical Market Share, by Region, 2024 & 2030, USD Million
11.2. North America
11.2.1. North America Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.2.2. U.S.
11.2.2.1. Key Country Dynamics
11.2.2.2. Target Disease Prevalence
11.2.2.3. Regulatory Framework
11.2.2.4. Reimbursement Framework
11.2.2.5. U.S. Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.2.3. Canada
11.2.3.1. Key Country Dynamics
11.2.3.2. Target Disease Prevalence
11.2.3.3. Regulatory Framework
11.2.3.4. Reimbursement Framework
11.2.3.5. U.S. Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.2.4. Mexico
11.2.4.1. Key Country Dynamics
11.2.4.2. Target Disease Prevalence
11.2.4.3. Regulatory Framework
11.2.4.4. Reimbursement Framework
11.2.4.5. Mexico Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.3. Europe
11.3.1. Europe Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.3.2. UK
11.3.2.1. Key Country Dynamics
11.3.2.2. Target Disease Prevalence
11.3.2.3. Regulatory Framework
11.3.2.4. Reimbursement Framework
11.3.2.5. Uk Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.3.3. Germany
11.3.3.1. Key Country Dynamics
11.3.3.2. Target Disease Prevalence
11.3.3.3. Regulatory Framework
11.3.3.4. Reimbursement Framework
11.3.3.5. Germany Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.3.4. France
11.3.4.1. Key Country Dynamics
11.3.4.2. Target Disease Prevalence
11.3.4.3. Regulatory Framework
11.3.4.4. Reimbursement Framework
11.3.4.5. France Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.3.5. Italy
11.3.5.1. Key Country Dynamics
11.3.5.2. Target Disease Prevalence
11.3.5.3. Regulatory Framework
11.3.5.4. Reimbursement Framework
11.3.5.5. Italy Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.3.6. Spain
11.3.6.1. Key Country Dynamics
11.3.6.2. Target Disease Prevalence
11.3.6.3. Regulatory Framework
11.3.6.4. Reimbursement Framework
11.3.6.5. Spain Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.3.7. Denmark
11.3.7.1. Key Country Dynamics
11.3.7.2. Target Disease Prevalence
11.3.7.3. Regulatory Framework
11.3.7.4. Reimbursement Framework
11.3.7.5. Denmark Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.3.8. Sweden
11.3.8.1. Key Country Dynamics
11.3.8.2. Target Disease Prevalence
11.3.8.3. Regulatory Framework
11.3.8.4. Reimbursement Framework
11.3.8.5. Sweden Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.3.9. Norway
11.3.9.1. Key Country Dynamics
11.3.9.2. Target Disease Prevalence
11.3.9.3. Regulatory Framework
11.3.9.4. Reimbursement Framework
11.3.9.5. Norway Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.4. Asia Pacific
11.4.1. Asia Pacific Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.4.2. Japan
11.4.2.1. Key Country Dynamics
11.4.2.2. Target Disease Prevalence
11.4.2.3. Regulatory Framework
11.4.2.4. Reimbursement Framework
11.4.2.5. Japan Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.4.3. China
11.4.3.1. Key Country Dynamics
11.4.3.2. Target Disease Prevalence
11.4.3.3. Regulatory Framework
11.4.3.4. Reimbursement Framework
11.4.3.5. China Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.4.4. India
11.4.4.1. Key Country Dynamics
11.4.4.2. Target Disease Prevalence
11.4.4.3. Regulatory Framework
11.4.4.4. Reimbursement Framework
11.4.4.5. India Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.4.5. Australia
11.4.5.1. Key Country Dynamics
11.4.5.2. Target Disease Prevalence
11.4.5.3. Regulatory Framework
11.4.5.4. Reimbursement Framework
11.4.5.5. Australia Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.4.6. South Korea
11.4.6.1. Key Country Dynamics
11.4.6.2. Target Disease Prevalence
11.4.6.3. Regulatory Framework
11.4.6.4. Reimbursement Framework
11.4.6.5. South Korea Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.4.7. Thailand
11.4.7.1. Key Country Dynamics
11.4.7.2. Target Disease Prevalence
11.4.7.3. Regulatory Framework
11.4.7.4. Reimbursement Framework
11.4.7.5. Thailand Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.5. Latin America
11.5.1. Latin America Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.5.2. Brazil
11.5.2.1. Key Country Dynamics
11.5.2.2. Target Disease Prevalence
11.5.2.3. Regulatory Framework
11.5.2.4. Reimbursement Framework
11.5.2.5. Japan Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.5.3. Argentina
11.5.3.1. Key Country Dynamics
11.5.3.2. Target Disease Prevalence
11.5.3.3. Regulatory Framework
11.5.3.4. Reimbursement Framework
11.5.3.5. China Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.6. Middle East and Africa
11.6.1. Middle East and Africa Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.6.2. South Africa
11.6.2.1. Key Country Dynamics
11.6.2.2. Target Disease Prevalence
11.6.2.3. Regulatory Framework
11.6.2.4. Reimbursement Framework
11.6.2.5. South Africa Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.6.3. Saudi Arabia
11.6.3.1. Key Country Dynamics
11.6.3.2. Target Disease Prevalence
11.6.3.3. Regulatory Framework
11.6.3.4. Reimbursement Framework
11.6.3.5. Saudi Arabia Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.6.4. UAE
11.6.4.1. Key Country Dynamics
11.6.4.2. Target Disease Prevalence
11.6.4.3. Regulatory Framework
11.6.4.4. Reimbursement Framework
11.6.4.5. UAE Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
11.6.5. Kuwait
11.6.5.1. Key Country Dynamics
11.6.5.2. Target Disease Prevalence
11.6.5.3. Regulatory Framework
11.6.5.4. Reimbursement Framework
11.6.5.5. Kuwait Pharmaceutical Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 12. Competitive Landscape
12.1. Recent Developments & Impact Analysis by Key Market Participants
12.2. Company Categorization
12.3. Participant Overview
12.4. Financial Performance
12.5. Product Bench Marking
12.6. Company Market Share Analysis, 2024
12.7. Company Profiles
12.7.1. F. Hoffmann-La Roche Ltd
12.7.1.1. Participant’s Overview
12.7.1.2. Financial Performance
12.7.1.3. Product Benchmarking
12.7.1.4. Recent Developments/ Strategic Initiatives
12.7.2. Novartis AG
12.7.2.1. Participant’s Overview
12.7.2.2. Financial Performance
12.7.2.3. Product Benchmarking
12.7.2.4. Recent Developments/ Strategic Initiatives
12.7.3. AbbVie Inc.
12.7.3.1. Participant’s Overview
12.7.3.2. Financial Performance
12.7.3.3. Product Benchmarking
12.7.3.4. Recent Developments/ Strategic Initiatives
12.7.4. Johnson & Johnson Services, Inc.
12.7.4.1. Participant’s Overview
12.7.4.2. Financial Performance
12.7.4.3. Product Benchmarking
12.7.4.4. Recent Developments/ Strategic Initiatives
12.7.5. Merck & Co., Inc.
12.7.5.1. Participant’s Overview
12.7.5.2. Financial Performance
12.7.5.3. Product Benchmarking
12.7.5.4. Recent Developments/ Strategic Initiatives
12.7.6. Pfizer Inc.
12.7.6.1. Participant’s Overview
12.7.6.2. Financial Performance
12.7.6.3. Product Benchmarking
12.7.6.4. Recent Developments/ Strategic Initiatives
12.7.7. Bristol-Myers Squibb Company
12.7.7.1. Participant’s Overview
12.7.7.2. Financial Performance
12.7.7.3. Product Benchmarking
12.7.7.4. Recent Developments/ Strategic Initiatives
12.7.8. Sanofi
12.7.8.1. Participant’s Overview
12.7.8.2. Financial Performance
12.7.8.3. Product Benchmarking
12.7.8.4. Recent Developments/ Strategic Initiatives
12.7.9. GlaxoSmithKline plc.
12.7.9.1. Participant’s Overview
12.7.9.2. Financial Performance
12.7.9.3. Product Benchmarking
12.7.9.4. Recent Developments/ Strategic Initiatives
12.7.10. AstraZeneca
12.7.10.1. Participant’s Overview
12.7.10.2. Financial Performance
12.7.10.3. Product Benchmarking
12.7.10.4. Recent Developments/ Strategic Initiatives
12.7.11. Takeda Pharmaceutical Co., Ltd.
12.7.11.1. Participant’s Overview
12.7.11.2. Financial Performance
12.7.11.3. Product Benchmarking
12.7.11.4. Recent Developments/ Strategic Initiatives
Chapter 13. Conclusion
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Pharmaceutical Market, by Molecule Type, 2018-2030 (USD Billion)
Table 4 Global Pharmaceutical Market, by Product, 2018-2030 (USD Billion)
Table 5 Global Pharmaceutical Market, by Type, 2018-2030 (USD Billion)
Table 6 Global Pharmaceutical Market, by Diseases, 2018-2030 (USD Billion)
Table 7 Global Pharmaceutical Market, by Route of Administration, 2018-2030 (USD Billion)
Table 8 Global Pharmaceutical Market, by Age Group, 2018-2030 (USD Billion)
Table 9 Global Pharmaceutical Market, by Distribution Channel, 2018-2030 (USD Billion)
Table 10 North America Pharmaceutical Market, by Country, 2018-2030 (USD Billion)
Table 11 North America Pharmaceutical Market, by Molecule Type, 2018-2030 (USD Billion)
Table 12 North America Pharmaceutical Market, by Product, 2018-2030 (USD Billion)
Table 13 North America Pharmaceutical Market, by Type, 2018-2030 (USD Billion)
Table 14 North America Pharmaceutical Market, by Diseases, 2018-2030 (USD Billion)
Table 15 North America Pharmaceutical Market, by Route of Administration, 2018-2030 (USD Billion)
Table 16 North America Pharmaceutical Market, by Age Group, 2018-2030 (USD Billion)
Table 17 North America Pharmaceutical Market, by Distribution Channel, 2018-2030 (USD Billion)
Table 18 U.S. Pharmaceutical Market, by Molecule Type, 2018-2030 (USD Billion)
Table 19 U.S. Pharmaceutical Market, by Product, 2018-2030 (USD Billion)
Table 20 U.S. Pharmaceutical Market, by Type, 2018-2030 (USD Billion)
Table 21 U.S. Pharmaceutical Market, by Diseases, 2018-2030 (USD Billion)
Table 22 U.S. Pharmaceutical Market, by Route of Administration, 2018-2030 (USD Billion)
Table 23 U.S. Pharmaceutical Market, by Age Group, 2018-2030 (USD Billion)
Table 24 U.S. Pharmaceutical Market, by Distribution Channel, 2018-2030 (USD Billion)
Table 25 Canada Pharmaceutical Market, by Molecule Type, 2018-2030 (USD Billion)
Table 26 Canada Pharmaceutical Market, by Product, 2018-2030 (USD Billion)
Table 27 Canada Pharmaceutical Market, by Type, 2018-2030 (USD Billion)
Table 28 Canada Pharmaceutical Market, by Diseases, 2018-2030 (USD Billion)
Table 29 Canada Pharmaceutical Market, by Route of Administration, 2018-2030 (USD Billion)
Table 30 Canada Pharmaceutical Market, by Age Group, 2018-2030 (USD Billion)
Table 31 Canada Pharmaceutical Market, by Distribution Channel, 2018-2030 (USD Billion)
Table 32 Europe Pharmaceutical Market, by Country, 2018-2030 (USD Billion)
Table 33 Europe Pharmaceutical Market, by Molecule Type, 2018-2030 (USD Billion)
Table 34 Europe Pharmaceutical Market, by Product, 2018-2030 (USD Billion)
Table 35 Europe Pharmaceutical Market, by Type, 2018-2030 (USD Billion)
Table 36 Europe Pharmaceutical Market, by Diseases, 2018-2030 (USD Billion)
Table 37 Europe Pharmaceutical Market, by Route of Administration, 2018-2030 (USD Billion)
Table 38 Europe Pharmaceutical Market, by Age Group, 2018-2030 (USD Billion)
Table 39 Europe Pharmaceutical Market, by Distribution Channel, 2018-2030 (USD Billion)
Table 40 Germany Pharmaceutical Market, by Molecule Type, 2018-2030 (USD Billion)
Table 41 Germany Pharmaceutical Market, by Product, 2018-2030 (USD Billion)
Table 42 Germany Pharmaceutical Market, by Type, 2018-2030 (USD Billion)
Table 43 Germany Pharmaceutical Market, by Diseases, 2018-2030 (USD Billion)
Table 44 Germany Pharmaceutical Market, by Route of Administration, 2018-2030 (USD Billion)
Table 45 Germany Pharmaceutical Market, by Age Group, 2018-2030 (USD Billion)
Table 46 Germany Pharmaceutical Market, by Distribution Channel, 2018-2030 (USD Billion)
Table 47 UK Pharmaceutical Market, by Molecule Type, 2018-2030 (USD Billion)
Table 48 UK Pharmaceutical Market, by Product, 2018-2030 (USD Billion)
Table 49 UK Pharmaceutical Market, by Type, 2018-2030 (USD Billion)
Table 50 UK Pharmaceutical Market, by Diseases, 2018-2030 (USD Billion)
Table 51 UK Pharmaceutical Market, by Route of Administration, 2018-2030 (USD Billion)
Table 52 UK Pharmaceutical Market, by Age Group, 2018-2030 (USD Billion)
Table 53 UK Pharmaceutical Market, by Distribution Channel, 2018-2030 (USD Billion)
Table 54 France Pharmaceutical Market, by Molecule Type, 2018-2030 (USD Billion)
Table 55 France Pharmaceutical Market, by Product, 2018-2030 (USD Billion)
Table 56 France Pharmaceutical Market, by Type, 2018-2030 (USD Billion)
Table 57 France Pharmaceutical Market, by Diseases, 2018-2030 (USD Billion)
Table 58 France Pharmaceutical Market, by Route of Administration, 2018-2030 (USD Billion)
Table 59 France Pharmaceutical Market, by Age Group, 2018-2030 (USD Billion)
Table 60 France Pharmaceutical Market, by Distribution Channel, 2018-2030 (USD Billion)
Table 61 Italy Pharmaceutical Market, by Molecule Type, 2018-2030 (USD Billion)
Table 62 Italy Pharmaceutical Market, by Product, 2018-2030 (USD Billion)
Table 63 Italy Pharmaceutical Market, by Type, 2018-2030 (USD Billion)
Table 64 Italy Pharmaceutical Market, by Diseases, 2018-2030 (USD Billion)
Table 65 Italy Pharmaceutical Market, by Route of Administration, 2018-2030 (USD Billion)
Table 66 Italy Pharmaceutical Market, by Age Group, 2018-2030 (USD Billion)
Table 67 Italy Pharmaceutical Market, by Distribution Channel, 2018-2030 (USD Billion)
Table 68 Spain Pharmaceutical Market, by Molecule Type, 2018-2030 (USD Billion)
Table 69 Spain Pharmaceutical Market, by Product, 2018-2030 (USD Billion)
Table 70 Spain Pharmaceutical Market, by Type, 2018-2030 (USD Billion)
Table 71 Spain Pharmaceutical Market, by Diseases, 2018-2030 (USD Billion)
Table 72 Spain Pharmaceutical Market, by Route of Administration, 2018-2030 (USD Billion)
Table 73 Spain Pharmaceutical Market, by Age Group, 2018-2030 (USD Billion)
Table 74 Spain Pharmaceutical Market, by Distribution Channel, 2018-2030 (USD Billion)
Table 75 Asia Pacific Pharmaceutical Market, by Country, 2018-2030 (USD Billion)
Table 76 Asia Pacific Pharmaceutical Market, by Molecule Type, 2018-2030 (USD Billion)
Table 77 Asia Pacific Pharmaceutical Market, by Product, 2018-2030 (USD Billion)
Table 78 Asia Pacific Pharmaceutical Market, by Type, 2018-2030 (USD Billion)
Table 79 Asia Pacific Pharmaceutical Market, by Diseases, 2018-2030 (USD Billion)
Table 80 Asia Pacific Pharmaceutical Market, by Route of Administration, 2018-2030 (USD Billion)
Table 81 Asia Pacific Pharmaceutical Market, by Age Group, 2018-2030 (USD Billion)
Table 82 Asia Pacific Pharmaceutical Market, by Distribution Channel, 2018-2030 (USD Billion)
Table 83 China Pharmaceutical Market, by Molecule Type, 2018-2030 (USD Billion)
Table 84 China Pharmaceutical Market, by Product, 2018-2030 (USD Billion)
Table 85 China Pharmaceutical Market, by Type, 2018-2030 (USD Billion)
Table 86 China Pharmaceutical Market, by Diseases, 2018-2030 (USD Billion)
Table 87 China Pharmaceutical Market, by Route of Administration, 2018-2030 (USD Billion)
Table 88 China Pharmaceutical Market, by Age Group, 2018-2030 (USD Billion)
Table 89 China Pharmaceutical Market, by Distribution Channel, 2018-2030 (USD Billion)
Table 90 Japan Pharmaceutical Market, by Molecule Type, 2018-2030 (USD Billion)
Table 91 Japan Pharmaceutical Market, by Product, 2018-2030 (USD Billion)
Table 92 Japan Pharmaceutical Market, by Type, 2018-2030 (USD Billion)
Table 93 Japan Pharmaceutical Market, by Diseases, 2018-2030 (USD Billion)
Table 94 Japan Pharmaceutical Market, by Route of Administration, 2018-2030 (USD Billion)
Table 95 Japan Pharmaceutical Market, by Age Group, 2018-2030 (USD Billion)
Table 96 Japan Pharmaceutical Market, by Distribution Channel, 2018-2030 (USD Billion)
Table 97 India Pharmaceutical Market, by Molecule Type, 2018-2030 (USD Billion)
Table 98 India Pharmaceutical Market, by Product, 2018-2030 (USD Billion)
Table 99 India Pharmaceutical Market, by Type, 2018-2030 (USD Billion)
Table 100 India Pharmaceutical Market, by Diseases, 2018-2030 (USD Billion)
Table 101 India Pharmaceutical Market, by Route of Administration, 2018-2030 (USD Billion)
Table 102 India Pharmaceutical Market, by Age Group, 2018-2030 (USD Billion)
Table 103 India Pharmaceutical Market, by Distribution Channel, 2018-2030 (USD Billion)
Table 104 Middle East Pharmaceutical Market, by Country, 2018-2030 (USD Billion)
Table 105 Middle East Pharmaceutical Market, by Molecule Type, 2018-2030 (USD Billion)
Table 106 Middle East Pharmaceutical Market, by Product, 2018-2030 (USD Billion)
Table 107 Middle East Pharmaceutical Market, by Type, 2018-2030 (USD Billion)
Table 108 Middle East Pharmaceutical Market, by Diseases, 2018-2030 (USD Billion)
Table 109 Middle East Pharmaceutical Market, by Route of Administration, 2018-2030 (USD Billion)
Table 110 Middle East Pharmaceutical Market, by Age Group, 2018-2030 (USD Billion)
Table 111 Middle East Pharmaceutical Market, by Distribution Channel, 2018-2030 (USD Billion)
Table 112 Saudi Arabia Pharmaceutical Market, by Molecule Type, 2018-2030 (USD Billion)
Table 113 Saudi Arabia Pharmaceutical Market, by Product, 2018-2030 (USD Billion)
Table 114 Saudi Arabia Pharmaceutical Market, by Type, 2018-2030 (USD Billion)
Table 115 Saudi Arabia Pharmaceutical Market, by Diseases, 2018-2030 (USD Billion)
Table 116 Saudi Arabia Pharmaceutical Market, by Route of Administration, 2018-2030 (USD Billion)
Table 117 Saudi Arabia Pharmaceutical Market, by Age Group, 2018-2030 (USD Billion)
Table 118 Saudi Arabia Pharmaceutical Market, by Distribution Channel, 2018-2030 (USD Billion)
Table 119 UAE Pharmaceutical Market, by Molecule Type, 2018-2030 (USD Billion)
Table 120 UAE Pharmaceutical Market, by Product, 2018-2030 (USD Billion)
Table 121 UAE Pharmaceutical Market, by Type, 2018-2030 (USD Billion)
Table 122 UAE Pharmaceutical Market, by Diseases, 2018-2030 (USD Billion)
Table 123 UAE Pharmaceutical Market, by Route of Administration, 2018-2030 (USD Billion)
Table 124 UAE Pharmaceutical Market, by Age Group, 2018-2030 (USD Billion)
Table 125 UAE Pharmaceutical Market, by Distribution Channel, 2018-2030 (USD Billion)
Table 126 Kuwait Pharmaceutical Market, by Molecule Type, 2018-2030 (USD Billion)
Table 127 Kuwait Pharmaceutical Market, by Product, 2018-2030 (USD Billion)
Table 128 Kuwait Pharmaceutical Market, by Type, 2018-2030 (USD Billion)
Table 129 Kuwait Pharmaceutical Market, by Diseases, 2018-2030 (USD Billion)
Table 130 Kuwait Pharmaceutical Market, by Route of Administration, 2018-2030 (USD Billion)
Table 131 Kuwait Pharmaceutical Market, by Age Group, 2018-2030 (USD Billion)
Table 132 Kuwait Pharmaceutical Market, by Distribution Channel, 2018-2030 (USD Billion)
List of Figures
Figure 1 Market Research Process
Figure 2 Information Procurement
Figure 3 Primary Research Pattern
Figure 4 Market Research Approaches
Figure 5 Value Chain-Based Sizing & Forecasting
Figure 6 Market Formulation & Validation
Figure 7 Pharmaceutical Market Segmentation
Figure 8 Market Driver Relevance Analysis (Current & Future Impact)
Figure 9 Market Restraint Relevance Analysis (Current & Future Impact)
Figure 10 Market Challenge Relevance Analysis (Current & Future Impact)
Figure 11 Penetration & Growth Prospect Mapping
Figure 12 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
Figure 13 Porter’s Five Forces Analysis
Figure 14 Pharmaceutical market: Molecule type outlook and key takeaways
Figure 15 Pharmaceutical market: Molecule type movement analysis & market share 2024 & 2030
Figure 16 Biologics & biosimilars (large molecules) market, 2018-2030 (USD Billion)
Figure 17 Monoclonal Antibodies market, 2018-2030 (USD Billion)
Figure 18 Vaccines market, 2018-2030 (USD Billion)
Figure 19 Cell & Gene Therapy market, 2018-2030 (USD Billion)
Figure 20 Others market, 2018-2030 (USD Billion)
Figure 21 Conventional drugs (small molecules) market, 2018-2030 (USD Billion)
Figure 22 Pharmaceutical market: Product outlook and key takeaways
Figure 23 Pharmaceutical market: Product movement analysis & market share 2024 & 2030
Figure 24 Branded pharmaceutical market, 2018-2030 (USD Billion)
Figure 25 Generics pharmaceutical market, 2018-2030 (USD Billion)
Figure 26 Pharmaceutical market: Type outlook and key takeaways
Figure 27 Pharmaceutical market: Type movement analysis & market share 2024 & 2030
Figure 28 Prescription pharmaceutical market, 2018-2030 (USD Billion)
Figure 29 OTC pharmaceutical market, 2018-2030 (USD Billion)
Figure 30 Pharmaceutical market: Disease outlook and key takeaways
Figure 31 Pharmaceutical market: Disease movement analysis & market share 2024 & 2030
Figure 32 Cancer market, 2018-2030 (USD Billion)
Figure 33 Cardiovascular diseases market, 2018-2030 (USD Billion)
Figure 34 Diabetes market, 2018-2030 (USD Billion)
Figure 35 Infectious diseases market, 2018-2030 (USD Billion)
Figure 36 Neurological disorders market, 2018-2030 (USD Billion)
Figure 37 Respiratory diseases market, 2018-2030 (USD Billion)
Figure 38 Autoimmune diseases market, 2018-2030 (USD Billion)
Figure 39 Mental health disorders market, 2018-2030 (USD Billion)
Figure 40 Gastrointestinal diseases market, 2018-2030 (USD Billion)
Figure 41 Women’s health diseases market, 2018-2030 (USD Billion)
Figure 42 Genetic and rare genetic diseases market, 2018-2030 (USD Billion)
Figure 43 Dermatological conditions market, 2018-2030 (USD Billion)
Figure 44 Obesity market, 2018-2030 (USD Billion)
Figure 45 Renal diseases market, 2018-2030 (USD Billion)
Figure 46 Liver conditions market, 2018-2030 (USD Billion)
Figure 47 Hemotological disorders market, 2018-2030 (USD Billion)
Figure 48 Eye conditions market, 2018-2030 (USD Billion)
Figure 49 Infertility conditions market, 2018-2030 (USD Billion)
Figure 50 Endocrine disorders market, 2018-2030 (USD Billion)
Figure 51 Allergies market, 2018-2030 (USD Billion)
Figure 52 Other diseases market, 2018-2030 (USD Billion)
Figure 53 Pharmaceutical market: Route of administration outlook and key takeaways
Figure 54 Pharmaceutical market: Route of administration movement analysis & market share 2024 & 2030
Figure 55 Oral pharmaceutical market, 2018-2030 (USD Billion)
Figure 56 Tablets pharmaceutical market, 2018-2030 (USD Billion)
Figure 57 Capsules pharmaceutical market, 2018-2030 (USD Billion)
Figure 58 Suspensions pharmaceutical market, 2018-2030 (USD Billion)
Figure 59 Others formulation pharmaceutical market, 2018-2030 (USD Billion)
Figure 60 Topical pharmaceutical market, 2018-2030 (USD Billion)
Figure 61 Parenteral pharmaceutical market, 2018-2030 (USD Billion)
Figure 62 Intravenous market, 2018-2030 (USD Billion)
Figure 63 Intramuscular market, 2018-2030 (USD Billion)
Figure 64 Inhalations pharmaceutical market, 2018-2030 (USD Billion)
Figure 65 Others pharmaceutical market, 2018-2030 (USD Billion)
Figure 66 Pharmaceutical market: Age group outlook and key takeaways
Figure 67 Pharmaceutical market: Age group movement analysis & market share 2024 & 2030
Figure 68 Children & Adolescents pharmaceutical market, 2018-2030 (USD Billion)
Figure 69 Adults pharmaceutical market, 2018-2030 (USD Billion)
Figure 70 Geriatric pharmaceutical market, 2018-2030 (USD Billion)
Figure 71 Pharmaceutical market: Distribution Channel outlook and key takeaways
Figure 72 Pharmaceutical market: Distribution Channel movement analysis & market share 2024 & 2030
Figure 73 Hospital Pharmacy pharmaceutical market, 2018-2030 (USD Billion)
Figure 74 Retail Pharmacy pharmaceutical market, 2018-2030 (USD Billion)
Figure 75 Others pharmaceutical market, 2018-2030 (USD Billion
Figure 76 Regional Outlook, 2024 & 2030
Figure 77 Regional Market Dashboard
Figure 78 Regional Market Place: Key Takeaways
Figure 79 North America
Figure 80 North America Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 81 U.S. Key Country Dynamics
Figure 82 U.S. Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 83 Canada Key Country Dynamics
Figure 84 Canada Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 85 Mexico Key Country Dynamics
Figure 86 Mexico Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 87 Europe
Figure 88 Europe Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 89 UK Key Country Dynamics
Figure 90 UK Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 91 Germany Key Country Dynamics
Figure 92 Germany Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 93 France Key Country Dynamics
Figure 94 France Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 95 Italy Key Country Dynamics
Figure 96 Italy Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 97 Spain Key Country Dynamics
Figure 98 Spain Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 99 Denmark Key Country Dynamics
Figure 100 Denmark Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 101 Sweden Key Country Dynamics
Figure 102 Sweden Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 103 Norway Key Country Dynamics
Figure 104 Norway Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 105 Asia Pacific
Figure 106 Asia-Pacific Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 107 Japan Key Country Dynamics
Figure 108 Japan Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 109 China Key Country Dynamics
Figure 110 China Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 111 India Key Country Dynamics
Figure 112 India Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 113 Australia Key Country Dynamics
Figure 114 Australia Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 115 Thailand Key Country Dynamics
Figure 116 Thailand Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 117 South Korea Key Country Dynamics
Figure 118 South Korea Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 119 Latin America
Figure 120 Latin America Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 121 Brazil Key Country Dynamics
Figure 122 Brazil Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 123 Argentina Key Country Dynamics
Figure 124 Argentina Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 125 MEA
Figure 126 MEA Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 127 South Africa Key Country Dynamics
Figure 128 South Africa Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 129 Saudi Arabia Key Country Dynamics
Figure 130 Saudi Arabia Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 131 UAE Key Country Dynamics
Figure 132 UAE Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 133 Kuwait Key Country Dynamics
Figure 134 Kuwait Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 135 Strategy Mapping

Companies Mentioned

The major companies profiled in this Pharmaceutical market report include:
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • AbbVie Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Sanofi
  • GlaxoSmithKline plc.
  • AstraZeneca
  • Takeda Pharmaceutical Co., Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages250
PublishedFebruary 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 1.64 Trillion
Forecasted Market Value ( USD ) by 2030 $ 2.35 Trillion
Compound Annual Growth Rate6.1%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

Dopamine Agonist Market Size, Share & Trends Analysis Report by Drug (Non-Ergot Dopamine Agonists, Ergot Alkaloids), Route of Administration (Oral, Injectable), Application, Distribution Channel, and Region with Growth Forecasts, 2025-2030 - Product Image

Dopamine Agonist Market Size, Share & Trends Analysis Report by Drug (Non-Ergot Dopamine Agonists, Ergot Alkaloids), Route of Administration (Oral, Injectable), Application, Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • Report
  • 153 Pages
  • Global
From
Nucleic Acid-Based Drugs Market by Drug Type (Antisense Oligonucleotides, DNA/RNA Aptamers, mRNA-Based Therapeutics), Molecule Type (Large Molecule, Small Molecule), Route of Administration, Therapeutic Area, End-User - Global Forecast 2025-2030 - Product Image

Nucleic Acid-Based Drugs Market by Drug Type (Antisense Oligonucleotides, DNA/RNA Aptamers, mRNA-Based Therapeutics), Molecule Type (Large Molecule, Small Molecule), Route of Administration, Therapeutic Area, End-User - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Pharmaceutical Contract Sales Organizations Market Size, Share & Trends Analysis Report by Services (Personal, Non-Personal Promotion), Therapeutic Area, End Use (Pharma, Biopharma Companies), and Region with Growth Forecasts, 2025-2030 - Product Image

Pharmaceutical Contract Sales Organizations Market Size, Share & Trends Analysis Report by Services (Personal, Non-Personal Promotion), Therapeutic Area, End Use (Pharma, Biopharma Companies), and Region with Growth Forecasts, 2025-2030

  • Report
  • 150 Pages
  • Global
From
Specialty Pharmaceuticals Market by Type, Product, Distribution Channel - Global Forecast 2025-2030 - Product Image

Specialty Pharmaceuticals Market by Type, Product, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Injection Pen Market by Type (Disposable and Reusable Pens), Therapy (Diabetes Therapy (Insulin, GLP-1), Growth Hormone Therapy, Osteoporosis, Obesity, Fertility), End User (Homecare and Hospitals & Clinics), and Region - Global Forecast to 2030 - Product Image

Injection Pen Market by Type (Disposable and Reusable Pens), Therapy (Diabetes Therapy (Insulin, GLP-1), Growth Hormone Therapy, Osteoporosis, Obesity, Fertility), End User (Homecare and Hospitals & Clinics), and Region - Global Forecast to 2030

  • Report
  • 243 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.